Articles On Optiscan Imaging (ASX:OIL)

Title Source Codes Date
Hot Money Monday: The CAN SLIM method and how momentum investors can use it to make gains

Momentum investing involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. William J. O’Neil, the founder of Investor’s...

Stockhead OIL 1 week ago
Optiscan sets up shop in US biotech hub

Medical device manufacturer Optiscan Imaging has expanded its U.S push, opening an office in the biotech hub of Minnesota with two well-credentialed hires.

The West OIL 3 weeks ago
Closing Bell: ASX too timid on Tuesday. Although Dart Mining has a decent Mesoblast

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Stockhead OIL 3 weeks ago
Medtech Optiscan beefs up operations in US, hires two high-level execs

Special Report: Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal endomicroscopic imaging technologies.  Optiscan (ASX:OIL) has started to ramp up its presence in the US after...

Stockhead OIL 3 weeks ago
Optiscan Imaging announces the appointment of US clinical and regulatory heads

Optiscan Imaging (ASX:OIL) has announced the establishment of its US Regional Office in Rochester, Minnesota, and the appointment of two US-based heads of clinical and regulatory affairs.

BiotechDispatch OIL 3 weeks ago
Optiscan to power innovative imaging research with tax cash

Optiscan Imaging’s ongoing studies aimed at producing revolutionary medical imaging devices have received a timely financial boost through a $672,320 research and development tax rebate from the ATO.

The West OIL 1 month ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead OIL 1 month ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead OIL 1 month ago
These ASX biotechs want to tackle cancer head-on for better outcomes

Early detection and effective treatment can lead to remission or cure for many cancers Optiscan’s tech brings surgeons and pathologists together to better diagnose, treat and monitor cancer Race Oncology’s working to minimise cardiovascula...

Stockhead OIL 2 months ago
Long Shortz with Optiscan: Optiscan optimises AI in its fight against GI baddies

Stockhead’s Ashtyn Hiron sits down with Optiscan (ASX:OIL) CEO And Managing Director Dr. Camile Farah to get the short end of the long story on the company’s latest news. Optiscan received a $3 million dollar grant to work on its second-gen...

Stockhead OIL 2 months ago
Market Open: ASX200 braces for red Wednesday as US inflation comes in hotter than expected

US inflation data came in higher than tipped, rattling the markets over there, with the ripple effect expected to reach the ASX200 today. Futures predict the local share market will shed 1.5 per cent for Valentine’s Day. The Nasdaq tu...

themarketonline.com.au OIL 2 months ago
Optiscan looks to AI future with $3m grant

Optiscan Imaging is investigating how it can use AI in the cancer-fighting technology it believes could help create a multi-billion-dollar revenue stream in the United States, after receiving a $3m grant.

The West OIL 2 months ago
Revenue leap for Optiscan as cancer fight continues

A money trail is forming behind Optiscan Imaging’s technology-based mission to tackle the scourge of cancer, with revenue starting to stream into the company’s coffers from the lucrative Chinese health sector.

The West OIL 4 months ago
Optiscan’s platform could address global pathologist shortage

Optiscan’s platform could help with shortage of pathologists in Australia and globally Platform particularly useful in diagnosing malignant tumours and pre-cancerous lesions in surgery Optiscan seeking US FDA De Novo clearance for its InV...

Stockhead OIL 5 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead OIL 5 months ago
In Case You Missed It: A bumper brain cancer trial and solid lithium hits

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, which made announcements today.   ICYMI Lead...

Stockhead OIL 6 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead OIL 6 months ago
Optiscan moves to stamp stronger US footprint

Optiscan Imaging has strengthened its mission aimed at breaking into the US health market or with its “ViewnVivo” technology by putting key personnel on the ground on that country’s east and west coasts.

The West OIL 6 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead OIL 6 months ago
Optiscan on cusp of real-time cancer imaging breakthrough

Optiscan Imaging is on a mission to prove its technology can provide surgeons with the exact extent of breast cancer margins at the time of operating through the real-time diagnosis of affected tissues.

The West OIL 7 months ago
Optiscan Imaging correlates with histology in breast cancer study

Optiscan Imaging (ASX:OIL) has provided an interim readout on its Breast Cancer Intraoperative Assessment Study.

BiotechDispatch OIL 7 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead OIL 7 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead OIL 7 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead OIL 7 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead OIL 8 months ago
Optiscan clears key telepathology project milestone

Optiscan Imaging has ticked off a major milestone in developing its telepathology platform, with the project passing its proof-of-concept stage amid plans for the software to completed by the end of next year.

The West OIL 8 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead OIL 8 months ago
Optiscan secures $16.7m research and development funding

Optiscan Imaging says it has successfully raised $16.7 million from a recent entitlement issue as the company looks to pursue research and development projects, in addition to developing new clinical devices.

The West OIL 9 months ago
Optiscan gets speaking gig at key health conferences

Optiscan Imaging has been invited to present its remarkable confocal endomicroscopic medical imaging technology at two key international conferences in North and South America.

The West OIL 9 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead OIL 10 months ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead OIL 10 months ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead OIL 10 months ago
Optiscan Imaging launches entitlement offer to raise $16.7 million

Optiscan Imaging (ASX:OIL) has launched an entitlement offer to raise $16.7 million it says will be used to support its strategic portfolio expansion.

BiotechDispatch OIL 10 months ago
Optiscan on mission to revolutionise medical imaging

Optiscan Imaging has revealed a $16.7 million mission to fast-track the development of its revolutionary medical imagery devices. An entitlement offer has already been supported by two cornerstone investors.

The West OIL 10 months ago
Optiscan Imaging oral study published in international medical journal

Optiscan Imaging (ASX:OIL) has announced the publication of readout results of its oral cancer imaging study conducted by Dr Camile Farah and his team at the Australian Centre for Oral Oncology Research and Education.

BiotechDispatch OIL 11 months ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead OIL 11 months ago
Optiscan Imaging establishes US commercial operation in Minnesota

Australian company Optiscan Imaging (ASX:OIL) has announced the establishment of a new commercial operation in the US.

BiotechDispatch OIL 1 year ago
Why growth is a positive for the ASX medical imaging sector

The medical imaging market size globally is forecast to reach $68.8 Billion by 2030 Several ASX health imaging stocks are establishing strong footholds and niches in sector Micro-X branching out from the medical sphere with its bomb detect...

Stockhead OIL 1 year ago
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?

Several ASX health stocks are seeking US FDA approval for drugs/devices in the near future Telix Pharmaceuticals is chasing renal cancer imaging approval for TLX-250 CDx Aroa is awaiting an FDA decision on the required regulatory pathway...

Stockhead OIL 1 year ago
Interim analysis shows accuracy of Optiscan Imaging platform

Optiscan Imaging (ASX:OIL) has announced the interim results of its oral imaging study conducted at the Australian Centre for Oral Oncology Research and Education.

BiotechDispatch OIL 1 year ago
ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity

Patrys says pre-clinical data supports its drug’s synthetic lethality mechanism Alterity granted patent in the US Optiscan says 100% of cancer cases were diagnosed correctly using its device   Patrys’ PAT-DX3 shown to have ‘synthetic leth...

Stockhead OIL 1 year ago
Optiscan Imaging’s (ASX:OIL) technology proven “extremely accurate” for oral cancer diagnosis

A recent Optiscan Imaging (OIL) study shows the company’s technology is “extremely accurate” for the diagnosis of oral cancer and precancer The company has received interim results from its oral imaging study, where 47 patients were asse...

themarketherald.com.au OIL 1 year ago
Market Highlights: Gold, Bitcoin sharply up as US bank stocks crumble, and 5 ASX small caps to watch today

US bank stocks were rattled on concerns of a contagion from SVB collapse Bond yields tumbled, lifting rates sensitive shares like Tech Gold continues its climb on flight to safety   It was a volatile session on Wall Street overnight as co...

Stockhead OIL 1 year ago
Optiscan Imaging announces collaboration with Canadian-based company

Optiscan Imaging has announced an exclusive collaboration with Canadian-based Prolucid Technologies to develop AI algorithms and telepathology workflows using its confocal laser endomicroscopy technology.

BiotechDispatch OIL 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead OIL 1 year ago
Optiscan Imaging (ASX:OIL) partners with Prolucid to develop AI-based cancer detection tech

Optiscan Imaging (OIL) partners with software developer Prolucid Technologies to develop AI algorithms using confocal laser endomicroscopy (CLE) tech The companies will work to develop a processing pipeline to display the results of an A...

themarketherald.com.au OIL 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead OIL 1 year ago
CLOSING BELL: Because sometimes you just know when enough is enough

ASX 200 holds steady around +0.8% since lunch Australian Pacific Coal CEO David Conry has left the company. Abruptly. Bain Capital making all the right noises about bringing Virgin back to the bourse   All up, it’s been a pretty tidy old...

Stockhead OIL 1 year ago
Closing Bell: RBA tries (and fails) to dampen investor enthusiasm as ASX edges to 6mth high

ASX 200 edges higher,  small cap index falls 0.44% 7 out of 11 sectors were in the green with Tech up 1.25% Downbeat RBA Governor speech highlights all the things that could go wrong with the economy   Last night the leads were decent, th...

Stockhead OIL 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead OIL 1 year ago